Four years after Altos Labs closed a $3 billion Series A (the largest private biotech raise on record at the time), no partial reprogramming company has filed an Investigational New Drug application with the FDA, a clinical trial notification with Japan's PMDA, or a clinical trial authorization under Singapore's HSA Advanced Therapy Medicinal Products framework. The capital priced partial cellular reprogramming as a therapeutic platform. The science is elsewhere: the foundational published result, Lu et al. in Nature (2020), used OSK factor expression without c-MYC specifically because c-MYC co-expression in fully reprogramming approaches carries teratoma risk at doses required for systemic delivery. That risk is not a footnote in the primary literature. It is the central unresolved problem in translating this mechanism to a human therapeutic, and it does not feature in the valuation frameworks currently applied to the asset class.

APAC sovereign-adjacent and family-office capital has accumulated exposure through secondary positions in Altos and through dedicated biotech mandates at several Hong Kong-domiciled single-family offices. The argument used to justify near-term commercialization rests on two regulatory claims: that PMDA's conditional approval pathway under Japan's 2014 Act on the Safety of Regenerative Medicine compresses the clinical timeline, and that Singapore's HSA ATMP framework does the same. Both claims misread the frameworks. PMDA's Office of Cellular and Tissue-based Products requires a completed clinical trial in a Japanese population before conditional commercialization; the post-conditional confirmatory study requirement in the 2014 Act means commercial approval is rescinded on negative follow-up, not preserved by it. Singapore's Health Products (Cell, Tissue and Gene Therapy Products) Regulations require a completed first-in-human Phase 1 with Singapore-enrolled patients before conditional licensing. PMDA's Office of Cellular and Tissue-based Products and Singapore's HSA have received no first-in-human application for any partial reprogramming compound as of June 2026.